LYNN MACMASTER: Open Payments
NPI 1962070862 · MILFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,203 in 89 payments from 11 companies in 2025. Trend: 2023 $1,227 · 2024 $1,278 · 2025 $2,203
Food & beverage: $2,203
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $899 |
| Teva Pharmaceuticals USA, Inc. | 11 | $288 |
| ABBVIE INC. | 14 | $252 |
| Neurocrine BioSciences, Inc. | 8 | $175 |
| Janssen Pharmaceuticals, Inc | 8 | $169 |
| Indivior Inc. | 4 | $131 |
| Alkermes, Inc. | 4 | $107 |
| E.R. Squibb & Sons, L.L.C. | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Lundbeck LLC | 2 | $48 |
Products named: CAPLYTA, AUSTEDO XR, VRAYLAR, INGREZZA, INVEGA SUSTENNA, SUBLOCADE, ARISTADA, REXULTI.
Industry payments across CT — which companies pay providers there.
